SCHEMBL3272916

SCHEMBL3272916

O=C(C=Cc1ccc2ccccc2c1)Nc1cc(Cl)c(Cl)cc1S(=O)(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 5/20 0.49
MMP2 P08253 5/20 0.49
MMP9 P14780 5/20 0.49
HCAR2 Q8TDS4 1/20 0.47
EGFR P00533 2/20 0.46
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
HDAC1 Q13547 2/20 0.44
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
MEN1 O00255 1/20 0.44
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3272911 1.00 MMP1 (0.49) MMP1MMP2MMP9HCAR2EGFR
SCHEMBL3280717 0.87 EGFR (0.50) MMP1MMP2MMP9HCAR2EGFR
SCHEMBL3280709 0.87 EGFR (0.50) MMP1MMP2MMP9HCAR2EGFR
SCHEMBL3274105 0.81 PTGES2 (0.49) MMP1MMP2MMP9HCAR2MAOA
SCHEMBL3274111 0.81 PTGES2 (0.49) MMP1MMP2MMP9HCAR2MAOA
SCHEMBL27885246 0.81 MMP1 (0.71) MMP1MMP2MMP9HCAR2EGFR
SCHEMBL3273877 0.77 MAPT (0.50) MMP1MMP2MMP9HCAR2EGFR
SCHEMBL3273883 0.77 MAPT (0.50) MMP1MMP2MMP9HCAR2EGFR
SCHEMBL3273292 0.75 MMP1 (0.59) MMP1MMP2MMP9HCAR2EGFR
SCHEMBL3273286 0.75 MMP1 (0.59) MMP1MMP2MMP9HCAR2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-04-08 US claimed
EP-2121569-A2 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2009-11-25 EP claimed
WO-2008074755-A2 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2008-06-26 WO claimed
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-04-08 US disclosed
EP-2121569-A2 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2009-11-25 EP disclosed
WO-2008074755-A2 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS TRPV1, TRPA1, TRPM8 MMP1 4839/4885MMP2 4689/4885MMP9 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.